Major Depressive Disorder (MDD) is common psychiatric condition that causes significant disability and disease burden. Treatment for this condition may require multiple medication trials. Up to thirty percent of individuals with MDD do not receive adequate benefit from several antidepressant drug trials and are considered treatment resistant. The management of treatment resistant depression (TRD) often requires novel approaches. One such approach is to use N-methyl-D-aspartate (NMDA) receptor antagonists such as ketamine or esketamine. This session will review the use of ketamine and esketamine for TRD.
SPEAKERS
Matthew Fuller, PharmD, FASHP, BCPP received his B.S. in Pharmacy from Ohio Northern University and his Doctor of Pharmacy degree from the University of Cincinnati. He completed a residency in hospital pharmacy at Bethesda Hospital in Zanesville, OH. Following the completion of his training he joined the clinical staff at the Louis Stokes Cleveland Department of Veterans Affairs Medical Center in Cleveland, Ohio where he practiced as a Clinical Pharmacy Specialist, Psychiatry for over 32 years. Recently, he joined the VHA PBM and currently works as a National PBM Clinical Pharmacy Program Manager in Psychiatry and Geriatrics.
Bhavik Shah, PharmD, BCPS, BCIDP earned his doctorate of pharmacy from Rutgers University, and completed post-graduate training in pharmacy practice and infectious diseases at Thomas Jefferson University Hospital in Philadelphia, PA. He is an associate professor at the Jefferson College of Pharmacy and co-director of the Pharmacology thread in the JeffMD curriculum at SIdney Kimmel Medical College at Thomas Jefferson University. He is an active member of ASHP and ACCP. Within ASHP, he has served as vice-chair and is currently the chair of the Year-Round Educational Steering Committee for 2020-2021.